X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with PLETHICO PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs PLETHICO PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA PLETHICO PHARMA SHASUN PHARMA/
PLETHICO PHARMA
 
P/E (TTM) x 123.9 -1.1 - View Chart
P/BV x 8.5 0.0 50,911.7% View Chart
Dividend Yield % 0.2 0.0 -  

Financials

 SHASUN PHARMA   PLETHICO PHARMA
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
PLETHICO PHARMA
Mar-14
SHASUN PHARMA/
PLETHICO PHARMA
5-Yr Chart
Click to enlarge
High Rs94395 23.9%   
Low Rs4631 145.7%   
Sales per share (Unadj.) Rs214.2604.4 35.4%  
Earnings per share (Unadj.) Rs5.332.5 16.4%  
Cash flow per share (Unadj.) Rs15.851.3 30.8%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %1.40-  
Book value per share (Unadj.) Rs53.3473.6 11.3%  
Shares outstanding (eoy) m56.6234.08 166.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.30.4 92.6%   
Avg P/E ratio x13.16.6 199.7%  
P/CF ratio (eoy) x4.44.2 106.4%  
Price / Book Value ratio x1.30.5 291.2%  
Dividend payout %18.70-   
Avg Mkt Cap Rs m3,9587,262 54.5%   
No. of employees `000NANA-   
Total wages/salary Rs m2,1641,596 135.6%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m12,12720,598 58.9%  
Other income Rs m229386 59.4%   
Total revenues Rs m12,35620,984 58.9%   
Gross profit Rs m1,0092,818 35.8%  
Depreciation Rs m594642 92.4%   
Interest Rs m4151,593 26.1%   
Profit before tax Rs m230969 23.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-73-138 52.6%   
Profit after tax Rs m3021,107 27.3%  
Gross profit margin %8.313.7 60.8%  
Effective tax rate %-31.7-14.3 221.6%   
Net profit margin %2.55.4 46.4%  
BALANCE SHEET DATA
Current assets Rs m6,88418,877 36.5%   
Current liabilities Rs m8,45611,896 71.1%   
Net working cap to sales %-13.033.9 -38.2%  
Current ratio x0.81.6 51.3%  
Inventory Days Days6236 171.5%  
Debtors Days Days108198 54.4%  
Net fixed assets Rs m4,9709,861 50.4%   
Share capital Rs m113341 33.3%   
"Free" reserves Rs m2,87512,331 23.3%   
Net worth Rs m3,02016,139 18.7%   
Long term debt Rs m1,8174,706 38.6%   
Total assets Rs m13,34733,146 40.3%  
Interest coverage x1.61.6 96.6%   
Debt to equity ratio x0.60.3 206.4%  
Sales to assets ratio x0.90.6 146.2%   
Return on assets %5.48.1 66.0%  
Return on equity %10.06.9 145.9%  
Return on capital %13.312.3 108.4%  
Exports to sales %46.421.4 216.9%   
Imports to sales %14.215.2 93.6%   
Exports (fob) Rs m5,6224,402 127.7%   
Imports (cif) Rs m1,7283,136 55.1%   
Fx inflow Rs m5,8434,402 132.7%   
Fx outflow Rs m2,1733,184 68.3%   
Net fx Rs m3,6691,219 301.1%   
CASH FLOW
From Operations Rs m3982,437 16.3%  
From Investments Rs m-1,635-6,265 26.1%  
From Financial Activity Rs m1,3092,490 52.6%  
Net Cashflow Rs m71-1,337 -5.3%  

Share Holding

Indian Promoters % 39.2 82.7 47.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.6 4.3 83.7%  
FIIs % 17.6 5.5 320.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 7.5 528.0%  
Shareholders   20,750 10,665 194.6%  
Pledged promoter(s) holding % 12.3 85.7 14.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   TORRENT PHARMA  NATCO PHARMA  AJANTA PHARMA  SANOFI INDIA  ALEMBIC PHARMA  

Compare SHASUN PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

Revenge of the Ratings Agencies(Vivek Kaul's Diary)

Sep 7, 2018

Do you remember when ratings agencies ruled financial markets? Nick explains why he thinks it's time to prepare yourselves for a comeback of the ratings agencies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 5-YR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS